The GNMT-KO (GSE63027) had top upregulated pathways including fatty acid β-oxidation I, stearate biosynthesis I, antioxidant action of vitamin C, oxidative phosphorylation, glutaryl-CoA degradation kinase, triacylglycerol biosynthesis, and tricarboxylic acid cycle (TCA) cycle II, among which fatty acid β-oxidation I and stearate biosynthesis I were shared with the first human NASH (GSE17470). Here, GNMT is linked to metabolic dysfunction-associated steatohepatitis.